Vibhavadi Medical Center Public Company Limited (VIBHA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Vibhavadi Medical Center Public Company Limited stock THB 0.86, price THB 1.31, that is 34.4% below the price, quality 55 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 1.28 THB – 2.63 THB · fair‑value band 0.7000 THB – 1.10 THB · the 1.31 THB price screens above the 0.8600 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Vibhavadi Medical Center Public Company in your weekly email
Every Wednesday you see whether Vibhavadi Medical Center Public Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vibhavadi Medical Center Public Company Limited operates a hospital under the Vibhavadi Hospital name in Thailand. It operates through two segments, Hospital General Hospital and Hospital in Social Security; and Others Rental services and rental space.
Show moreShow less
The company provides medical services; and rental services and space rental. It engages in the beauty business; and operation of anti-aging center and specialized disease clinics. The company was founded in 1986 and is based in Bangkok, Thailand.
Stock analysis
Vibhavadi Medical Center Public Company Limited (VIBHA) currently trades at 1.31 THB, while our model-based Fair Value estimate is 0.8600 THB, 34% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 2.54 THB per share, and 7 of the 26 models we run sit above the 1.31 THB price.
Bear case: the Economic Profit group reads lowest at 0.5100 THB, and 19 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.7000 THB (bear) to 1.10 THB (bull), the price of 1.31 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2013: revenue and profit before it include the divested business. Growth is measured afresh from 2013.
Vibhavadi Medical Center Public Company Limited reported revenue of 5.6B THB in FY2025 versus 7.4B THB in FY2021, a compound −6.6%/yr. Reported net income was 1.7B THB in FY2025, compounding −1.6%/yr from FY2021.
Key figures
Market cap 17.7B THB (≈ $527M) Small · P/E ratio 9.4 · P/S ratio 3.16 · EPS (TTM) 0.1400 THB · Dividend yield 4.6% · Net margin 33.0% · Return on equity 17.3% · Return on assets (EBIT) 5.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −34%, VIBHA screens richer than that median.
Fair Value models
Bear0.7000 THBFair Value 0.8600 THBBull1.10 THB
Price 1.31 THB · Downside -34.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0684 THB per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2013: revenue and profit before it include the divested business. Growth is measured afresh from 2013.
Revenue growth 1 year
−34.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Start year 2020 (pandemic). Over 10 years: +0.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in THB (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+13.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.4%
Dividend (yield on the price)4.6%
Per share before 2013divided by the spin-off factor 1.1847
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.0% vs 9.4%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 12%
2025 sits 97% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+32.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Thailand: IMF forecast 1.2% a year to 2030, 1.1% from 2016 to 2025) that is about +30.7% a year for the price.
Compare Vibhavadi Medical Center Public Company Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Below median
Fair Value upside−34.4% · Below median
Profitability
Return on equity (12 months)17.3% · Top 25%
Return on assets7.8% · Above median
Net margin (12 months)33.0% · Top 25%
Operating margin (12 months)13.8% · Above median
Growth and dividend
Revenue growth (quarter YoY)−4.8% · Bottom 25%
Dividend yield (12 months)4.6% · Top 25%
Balance sheet
Debt / equity0.26× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Vibhavadi Medical Center Public Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/VIBHA
Frequently asked questions
Is Vibhavadi Medical Center Public Company Limited (VIBHA) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 0.8600 THB versus a price of 1.31 THB, about 34% lower (overvalued).
What is the fair value of VIBHA?
Our model-based fair value for Vibhavadi Medical Center Public Company Limited is 0.8600 THB (as of Nov 7, 2026), built from audited fundamentals. The current price: 1.31 THB.
What is the quality score of VIBHA?
Vibhavadi Medical Center Public Company Limited has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vibhavadi Medical Center Public Company Limited (VIBHA)?
Our model-based price target is the fair value of 0.8600 THB (as of Nov 7, 2026) from 26 valuation models. Cautious scenario 0.7000 THB, optimistic scenario 1.10 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Vibhavadi Medical Center Public Company Limited stock forecast for 2026?
Our models put fair value at 0.8600 THB, about 34% lower versus a price of 1.31 THB (overvalued). Cautious scenario 0.7000 THB, optimistic scenario 1.10 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Vibhavadi Medical Center Public Company Limited (VIBHA)?
Vibhavadi Medical Center Public Company Limited reported trailing-twelve-month revenue of about 5.6B THB (latest available figure, as of Nov 7, 2026).
Does Vibhavadi Medical Center Public Company Limited pay a dividend?
Vibhavadi Medical Center Public Company Limited currently shows a dividend yield of 4.58% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Vibhavadi Medical Center Public Company Limited (VIBHA) and when is the ex-dividend date?
Vibhavadi Medical Center Public Company Limited pays a dividend of 0.06 THB per share a year, a dividend yield of 4.6%. The last ex-dividend date was May 6, 2026. A dividend has been paid every year since 2002. The payout ratio is 42.9% of earnings. Free cash flow covers the dividend 0.70 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Vibhavadi Medical Center Public Company Limited (VIBHA)?
For today's price to be fair in a discounted-cash-flow model, Vibhavadi Medical Center Public Company Limited would have to grow free cash flow by +32.2 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.4 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of VIBHA use?
Our models discount Vibhavadi Medical Center Public Company Limited at 13.1 %: a base by market capitalisation (small), country premium for Thailand. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vibhavadi Medical Center Public Company Limited that is +32.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has Vibhavadi Medical Center Public Company Limited (VIBHA) delivered so far?
Over the past 5 years revenue at Vibhavadi Medical Center Public Company Limited grew -1.4 % a year. The price currently implies free-cash-flow growth of +32.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vibhavadi Medical Center Public Company Limited (VIBHA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Vibhavadi Medical Center Public Company Limited (+32.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vibhavadi Medical Center Public Company Limited (VIBHA)?
The free-cash-flow yield on the price is 3.20 %: that much free cash flow Vibhavadi Medical Center Public Company Limited produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vibhavadi Medical Center Public Company Limited (VIBHA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vibhavadi Medical Center Public Company Limited it is 0.8600 THB per share (as of Nov 7, 2026), against a price of 1.31 THB. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Vibhavadi Medical Center Public Company Limited stock overvalued or undervalued in 2026?
As of Nov 7, 2026, VIBHA trades above its calculated fair value: price 1.31 THB, fair value 0.8600 THB, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIBHA?
No. The price is what the market pays today (1.31 THB); the fair value is what the company's own numbers justify (0.8600 THB). For Vibhavadi Medical Center Public Company Limited the two are 0.4500 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Vibhavadi Medical Center Public Company Limited worth?
The market values Vibhavadi Medical Center Public Company Limited at about 17.7B THB (market capitalisation, as of Nov 7, 2026). Per share that is 1.31 THB; our models calculate a fair value of 0.8600 THB per share.
What do the bullish and bearish scenarios say about VIBHA?
Our models span a range for Vibhavadi Medical Center Public Company Limited: cautious scenario 0.7000 THB, base 0.8600 THB, optimistic 1.10 THB per share (as of Nov 7, 2026, price 1.31 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VIBHA?
Vibhavadi Medical Center Public Company Limited trades at a price-to-earnings ratio of 9.4 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.8600 THB is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 35.4. Other multiples: P/B 1.5, P/S 3.2, EV/EBITDA 13.7.
How solid is the balance sheet of Vibhavadi Medical Center Public Company Limited (VIBHA)?
Balance-sheet figures for Vibhavadi Medical Center Public Company Limited (as of Nov 7, 2026): return on equity 17.3%, debt of 0.26 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is VIBHA from its 52-week high?
Vibhavadi Medical Center Public Company Limited trades at 1.31 THB, about 6% below its 52-week high of 1.40 THB and 2% above the low of 1.28 THB (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.8600 THB is for.
Which stocks are comparable to Vibhavadi Medical Center Public Company Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vibhavadi Medical Center Public Company Limited stock attractive at the current price?
The data as of Nov 7, 2026: price 1.31 THB, calculated fair value 0.8600 THB (−34%), Quality Score 55/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VIBHA calculated?
We run Vibhavadi Medical Center Public Company Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.8600 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Vibhavadi Medical Center Public Company Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vibhavadi Medical Center Public Company Limited (VIBHA)?
The closing price on Nov 6, 2026 was 1.31 THB. Our model-based fair value is 0.8600 THB, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vibhavadi Medical Center Public Company Limited right now?
The price sits above even our optimistic bull case (1.10 THB). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Vibhavadi Medical Center Public Company Limited (VIBHA) come from?
Earnings per share at Vibhavadi Medical Center Public Company Limited grew +5.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.2 %, EBIT margin −2.1 %, tax rate +1.6 %, residual (interest, one-offs) +2.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Vibhavadi Medical Center Public Company Limited
How large is the market capitalisation of Vibhavadi Medical Center Public Company Limited (VIBHA)?
The market capitalisation of Vibhavadi Medical Center Public Company Limited is 17.7B THB (≈ $527M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vibhavadi Medical Center Public Company Limited (VIBHA)?
The price-to-sales ratio of Vibhavadi Medical Center Public Company Limited is 3.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vibhavadi Medical Center Public Company Limited (VIBHA)?
Earnings per share at Vibhavadi Medical Center Public Company Limited are 0.1400 THB (price ÷ EPS = P/E 9.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Vibhavadi Medical Center Public Company Limited (VIBHA)?
The dividend yield of Vibhavadi Medical Center Public Company Limited is 4.6% (payout 42.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Vibhavadi Medical Center Public Company Limited (VIBHA)?
The net margin of Vibhavadi Medical Center Public Company Limited is 33.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vibhavadi Medical Center Public Company Limited (VIBHA)?
The return on equity (ROE) of Vibhavadi Medical Center Public Company Limited is 17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vibhavadi Medical Center Public Company Limited (VIBHA)?
On an EBIT basis the return on assets of Vibhavadi Medical Center Public Company Limited is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vibhavadi Medical Center Public Company Limited (VIBHA)?
The operating margin of Vibhavadi Medical Center Public Company Limited is 13.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vibhavadi Medical Center Public Company Limited (VIBHA)?
Revenue at Vibhavadi Medical Center Public Company Limited is growing −4.8% versus a year earlier (3y avg −13.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vibhavadi Medical Center Public Company Limited (VIBHA)?
Earnings per share at Vibhavadi Medical Center Public Company Limited are growing +19.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vibhavadi Medical Center Public Company Limited (VIBHA) carry?
The net debt of Vibhavadi Medical Center Public Company Limited is 6.6B THB (fiscal year 2025, ≈ 11.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vibhavadi Medical Center Public Company Limited in the live analysis
One click puts Vibhavadi Medical Center Public Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026